Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Page standards status: Informative |
{
"resourceType" : "Composition",
"id" : "399873",
"meta" : {
"versionId" : "5",
"lastUpdated" : "2025-12-11T20:35:21.032Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-measure-report"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><p class=\"res-header-id\"><b>Generated Narrative: Composition 399873</b></p><a name=\"399873\"> </a><a name=\"hc399873\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 5; Last updated: 2025-12-11 20:35:21+0000; Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-outcome-measure-report.html\">OutcomeMeasureReport</a></p></div><p><b>url</b>: <a href=\"https://fevir.net/resources/Composition/399873\">https://fevir.net/resources/Composition/399873</a></p><p><b>identifier</b>: FEvIR Object Identifier/399873, FEvIR Linking Identifier/NCT03421379-outcome-measure-report</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 OutcomeMeasureReport}\">Outcome Measure Report</span></p><p><b>date</b>: 2025-12-11 20:35:21+0000</p><p><b>author</b>: [No author listed.]</p><p><b>title</b>: Outcome Measures Report for NCT03421379</p><p><b>custodian</b>: <a href=\"Organization-118079.html\">Computable Publishing LLC</a></p><h3>RelatesTos</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Target[x]</b></td></tr><tr><td style=\"display: none\">*</td><td>Cite As</td><td><div><p>Outcome Measures Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399873. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399873. Computable resource at: https://fevir.net/resources/Composition/399873#json.</p>\n</div></td></tr></table></div>"
},
"url" : "https://fevir.net/resources/Composition/399873",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net/FOI",
"value" : "399873",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
{
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-outcome-measure-report",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "OutcomeMeasureReport",
"display" : "OutcomeMeasureReport"
}
],
"text" : "Outcome Measure Report"
},
"date" : "2025-12-11T20:35:21.032Z",
"author" : [
{
"display" : "[No author listed.]"
}
],
"title" : "Outcome Measures Report for NCT03421379",
"custodian" : {
🔗 "reference" : "Organization/118079",
"type" : "Organization",
"display" : "Computable Publishing LLC"
},
"relatesTo" : [
{
"type" : "cite-as",
"targetMarkdown" : "Outcome Measures Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399873. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399873. Computable resource at: https://fevir.net/resources/Composition/399873#json."
}
],
"section" : [
{
"title" : "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration",
"focus" : {
🔗 "reference" : "EvidenceVariable/267226",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-primaryOutcome-0",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration (NCT03421379)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participant who completed both treatment visits and had evaluable treatment success data.</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose up to 30 minutes post each glucagon administration</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "Glucagon Nasal Powder",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"
},
"entry" : [
{
"display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
}
]
},
{
"title" : "Glucagon Hydrochloride Solution",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"
},
"entry" : [
{
"display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration (NCT03421379)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/267226",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-primaryOutcome-0",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration (NCT03421379)"
},
"entry" : [
{
🔗 "reference" : "Evidence/267232",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-primaryOutcomeMeasure-0--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379"
},
{
🔗 "reference" : "Evidence/267233",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-primaryOutcomeMeasure-0--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379"
},
{
🔗 "reference" : "Evidence/267244",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-primaryOutcomeMeasure-0-OutcomeAnalysis-0-BetweenGroupAnalysis-OG000-OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration Statistical Analysis for Glucagon Nasal Powder vs Glucagon Hydrochloride Solution in NCT03421379"
}
]
}
]
}
]
},
{
"title" : "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration",
"focus" : {
🔗 "reference" : "EvidenceVariable/267227",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-secondaryOutcome-0",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized patients who receive at least 1 dose of the study drug and have evaluable PD data.</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "Glucagon Nasal Powder",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"
},
"entry" : [
{
"display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
}
]
},
{
"title" : "Glucagon Hydrochloride Solution",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"
},
"entry" : [
{
"display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/267227",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-secondaryOutcome-0",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
},
"entry" : [
{
🔗 "reference" : "Evidence/267234",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-secondaryOutcomeMeasure-0--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379"
},
{
🔗 "reference" : "Evidence/267235",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-secondaryOutcomeMeasure-0--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379"
}
]
}
]
}
]
},
{
"title" : "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration",
"focus" : {
🔗 "reference" : "EvidenceVariable/267228",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-secondaryOutcome-1",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug and had evaluable PD data.</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "Glucagon Nasal Powder",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"
},
"entry" : [
{
"display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
}
]
},
{
"title" : "Glucagon Hydrochloride Solution",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"
},
"entry" : [
{
"display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/267228",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-secondaryOutcome-1",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
},
"entry" : [
{
🔗 "reference" : "Evidence/267236",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-secondaryOutcomeMeasure-1--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379"
},
{
🔗 "reference" : "Evidence/267237",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-secondaryOutcomeMeasure-1--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379"
}
]
}
]
}
]
},
{
"title" : "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration",
"focus" : {
🔗 "reference" : "EvidenceVariable/267229",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-secondaryOutcome-2",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug and had evaluable PK data.</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "Glucagon Nasal Powder",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"
},
"entry" : [
{
"display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
}
]
},
{
"title" : "Glucagon Hydrochloride Solution",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"
},
"entry" : [
{
"display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/267229",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-secondaryOutcome-2",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
},
"entry" : [
{
🔗 "reference" : "Evidence/267238",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-secondaryOutcomeMeasure-2--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379"
},
{
🔗 "reference" : "Evidence/267239",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-secondaryOutcomeMeasure-2--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379"
}
]
}
]
}
]
},
{
"title" : "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration",
"focus" : {
🔗 "reference" : "EvidenceVariable/267230",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-secondaryOutcome-3",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug and had evaluable PK data.</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "Glucagon Nasal Powder",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"
},
"entry" : [
{
"display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
}
]
},
{
"title" : "Glucagon Hydrochloride Solution",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"
},
"entry" : [
{
"display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/267230",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-secondaryOutcome-3",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
},
"entry" : [
{
🔗 "reference" : "Evidence/267240",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-secondaryOutcomeMeasure-3--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379"
},
{
🔗 "reference" : "Evidence/267241",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-secondaryOutcomeMeasure-3--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379"
}
]
}
]
}
]
},
{
"title" : "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration",
"focus" : {
🔗 "reference" : "EvidenceVariable/267231",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-secondaryOutcome-4",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
},
"section" : [
{
"title" : "Outcome Measure Population Description",
"code" : {
"text" : "OutcomeMeasurePopulationDescription"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug and had evaluable PK data.</div>"
}
},
{
"title" : "Outcome Measure Reporting Status",
"code" : {
"text" : "OutcomeMeasureReportingStatus"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title" : "Outcome Measure Time Frame",
"code" : {
"text" : "OutcomeMeasureTimeFrame"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>"
}
},
{
"title" : "Outcome Group List",
"code" : {
"text" : "OutcomeGroupList"
},
"section" : [
{
"title" : "Glucagon Nasal Powder",
"code" : {
"text" : "OG000"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"
},
"entry" : [
{
"display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
}
]
},
{
"title" : "Glucagon Hydrochloride Solution",
"code" : {
"text" : "OG001"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"
},
"entry" : [
{
"display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
}
]
}
]
},
{
"title" : "Outcome Class List",
"code" : {
"text" : "OutcomeClassList"
},
"section" : [
{
"title" : "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "results",
"display" : "Results"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/267231",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-secondaryOutcome-4",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
},
"entry" : [
{
🔗 "reference" : "Evidence/267242",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-secondaryOutcomeMeasure-4--OG000",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379"
},
{
🔗 "reference" : "Evidence/267243",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "NCT03421379-secondaryOutcomeMeasure-4--OG001",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379"
}
]
}
]
}
]
}
]
}
IG © 2024+ HL7 International / Clinical Decision Support.
Package hl7.fhir.uv.ebm#1.0.0-ballot3 based on FHIR 6.0.0-ballot3.
Generated
2026-02-10
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change